Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Pece S, Sestak I, Montani F, Tillhon M, Maisonneuve P, Freddi S, Chu K, Colleoni M, Veronesi P, Disalvatore D, Viale G, Buus R, Cuzick J, Dowsett M, Di Fiore PP. Pece S, et al. Among authors: buus r. Eur J Cancer. 2022 Mar;164:52-61. doi: 10.1016/j.ejca.2022.01.003. Epub 2022 Feb 15. Eur J Cancer. 2022. PMID: 35172273 Free article. Clinical Trial.
Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.
Lawler K, Papouli E, Naceur-Lombardelli C, Mera A, Ougham K, Tutt A, Kimbung S, Hedenfalk I, Zhan J, Zhang H, Buus R, Dowsett M, Ng T, Pinder SE, Parker P, Holmberg L, Gillett CE, Grigoriadis A, Purushotham A. Lawler K, et al. Among authors: buus r. Breast Cancer Res. 2017 Oct 13;19(1):113. doi: 10.1186/s13058-017-0881-y. Breast Cancer Res. 2017. PMID: 29029636 Free PMC article.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M. Sestak I, et al. Among authors: buus r. JAMA Oncol. 2018 Apr 1;4(4):545-553. doi: 10.1001/jamaoncol.2017.5524. JAMA Oncol. 2018. PMID: 29450494 Free PMC article. Clinical Trial.
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
Lopez-Knowles E, Pearson A, Schuster G, Gellert P, Ribas R, Yeo B, Cutts R, Buus R, Garcia-Murillas I, Haynes B, Martin LA, Smith I, Turner N, Dowsett M. Lopez-Knowles E, et al. Among authors: buus r. Br J Cancer. 2019 Jan;120(2):247-255. doi: 10.1038/s41416-018-0345-x. Epub 2018 Dec 19. Br J Cancer. 2019. PMID: 30563991 Free PMC article.
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Sestak I, Martín M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodríguez-Lescure A, Gnant M. Sestak I, et al. Among authors: buus r. Breast Cancer Res Treat. 2019 Jul;176(2):377-386. doi: 10.1007/s10549-019-05226-8. Epub 2019 Apr 30. Breast Cancer Res Treat. 2019. PMID: 31041683 Free PMC article.
63 results